EUCTR2016-000735-41-FR进行中（未招募）1 期
Antimicrobial treatment in patients with ventilator-associated tracheobronchitis: a prospective randomized placebo-controlled double-blind multicenter trial - TAVeM 2
CHRU LILLE0 个研究点目标入组 315 人开始时间: 2016年11月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 315
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All adult patients with a first episode of VAT diagnosed >48 hours after starting invasive mechanical ventilation are eligible for this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 315
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •long-term tracheostomy at ICU admission
- •-modified Clinical Pulmonary Infection Score (CPIS) =6 at the day of randomization
- •-patients who develop VAP before VAT
- •-patients already receiving antibiotics active against all the microorganisms responsible for VAT
- •-severe immunosuppression
- •-pregnancy or breastfeeding
- •-patients <18 years
- •-patients already included in another study, with potential interaction with the primary objective of the current study
- •-absence of social insurance
- •-patients under guardianship
- •-known resistance of bacteria responsible for VAT to imipenem and ciprofloxacin
- •-treatment limitation decisions
- •-moribund patients
- •-allergy to any of study drugs
研究者
相似试验
进行中（未招募）
不适用
Antibiotic treatment in patients hospitalized with an acute exacerbation in chronic obstructive pulmonary disease. Effect of one day of antibiotic treatment compared t0 6 days of antibiotic treatment in patients who are clinically stable 24 hours after hospitalization. A prospective, randomized, double-blind trial - TaexaCOPAcute exacerbation of chronic ostructive pulmonary disease in hospitalized patients. All patients receive standard of care, and 1 day of intravenous antibiotics. In addition patients are randomized to treatment with Vibradox 200 mg QD in 5 days or matching placebo. The primary outcome variable is 6 minutes walking distance at day 14 after hospitalization.MedDRA version: 9.1Level: LLTClassification code 10056971Term: Infective exacerbation of chronic obstructive airways diseaseEUCTR2007-007275-16-DKDepartment of Infetious Diseases, Odense University Hospital
进行中（未招募）
不适用
Antibiotic treatment for patients with infectious endocarditis: continuous infusion, guided by measurements of the antibiotic concentration in the blood, versus intermittent infusions (the CONTENT study).EUCTR2013-002807-32-DKAarhus University Hospital, Department of Cardiology40
进行中（未招募）
1 期
Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Careventilator associated neumonia in intensive careEUCTR2021-002197-78-FRAssistance Publique - Hôpitaux de Paris590
进行中（未招募）
1 期
ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONSCommunity acquired pneumoniaMedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862EUCTR2019-001873-10-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS310
终止
4 期
Antimicrobial Treatment in Patients With Ventilator-associated TracheobronchitisMechanical Ventilation ComplicationCritical IllnessNCT03012360University Hospital, Lille103